(Q43038365)

12 November 2017

0 references

1 reference

title

Favourable and disappointing lessons from viral kinetics (English)

1 reference

12 November 2017

1

Stefan Zeuzem

1 reference

12 November 2017

publication date

1 July 2002

1 reference

12 November 2017

published in

Journal of Hepatology

1 reference

12 November 2017

volume

37

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

151-153

1 reference

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900167-8

7 January 2021

10.1016/S0168-8278(02)00167-8

Identifiers

DOI

1 reference

12 November 2017

1 reference